A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/08 (2006.01) A61K 31/225 (2006.01) A61K 31/40 (2006.01) A61K 31/42 (2006.01) A61K 31/44 (2006.01) A61K 31/445 (2006.01) A61K 31/505 (2006.01) A61K 31/55 (2006.01) A61K 31/60 (2006.01) A61K 45/06 (2006.01)
Patent
CA 2265827
The instant invention involves a combination therapy and pharmaceutical compositions comprised of a therapeutically effective amount of a cholesterol reducing agent such as an HMG-CoA reductase inhibitor in combination with a platelet aggregation inhibitor which is useful for inhibiting platelet aggregation, for inhibiting the formation of thrombotic occlusions, and for treating, preventing and reducing the risk of occurrence of cardiovascular and cerebrovascular events and related vaso-occlusive disorders.
La présente invention a pour objet un traitement combiné et des compositions thérapeutiques comprenant une quantité efficace au point de vue thérapeutique d'un agent réducteur de cholestérol tel qu'un inhibiteur de la HMG CoA-réductase, combiné à un inhibiteur d'agrégation plaquettaire permettant d'inhiber l'agrégation plaquettaire et la formation d'occlusions thrombotiques et servant au traitement, à la prévention et à la réduction des risques d'accidents cardio-vasculaires et cérébrovasculaires et des troubles d'occlusion vasculaire qui y sont liés.
Gould Robert J.
Nichtberger Steven A.
Olofsson Lars
Rhymer Patricia A.
Merck & Co. Inc.
Ogilvy Renault Llp/s.e.n.c.r.l.,s.r.l.
LandOfFree
Combination therapy for reducing the risks associated with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapy for reducing the risks associated with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy for reducing the risks associated with... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1857166